SDR2SamuelRabkinSamuel Rabkin, Ph.D.42.36125700000000-71.0655270000000023518Rabkin, SamuelDavid617/726-6817Thomas A. Pappas Professor of Neurosciencescatalyst:advisorInMentoringCompletedStudentProjectcompleted student projectscatalyst:advisorInMentoringCurrentStudentOpportunitycurrent student opportunitiescatalyst:eCommonsLogineCommons LoginMentoring - Completed Student ProjectMentoring - Current Student Opportunityprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson10476216Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SDGene therapyHepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999 Apr; 6(4):564-72.Gene Ther1999-04-01T00:00:001999Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.29599413Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RLClinical cancer research : an official journal of the American Association for Cancer ResearchCombinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Clin Cancer Res. 2018 07 15; 24(14):3409-3422.Clin Cancer Res2018-03-29T00:00:002018Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.Curry WT, Martuza RL, Rabkin SDAbs Cong Neurol SurgG207 infection of dendritic cells: effects on maturation and generation of antitumor immunity. Abs Cong Neurol Surg. 2003; 53:753.2003-01-01T00:00:002003G207 infection of dendritic cells: effects on maturation and generation of antitumor immunityAuthorship 105523756185946Moore PD, Rabkin SD, Osborn AL, King CM, Strauss BSProceedings of the National Academy of Sciences of the United States of AmericaEffect of acetylated and deacetylated 2-aminofluorene adducts on in vitro DNA synthesis. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7166-70.Proc Natl Acad Sci U S A1982-12-01T00:00:001982Effect of acetylated and deacetylated 2-aminofluorene adducts on in vitro DNA synthesis.8542424Mineta T, Markert JM, Takamiya Y, Coen DM, Rabkin SD, Martuza RLGene therapyCNS tumor therapy by attenuated herpes simplex viruses. Gene Ther. 1994; 1 Suppl 1:S78.Gene Ther1994-01-01T00:00:001994CNS tumor therapy by attenuated herpes simplex viruses.Authorship 109549216278413Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo TClinical cancer research : an official journal of the American Association for Cancer ResearchOncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 2005 Nov 01; 11(21):7886-90.Clin Cancer Res2005-11-01T00:00:002005Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.17045531Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz AMolecular therapy : the journal of the American Society of Gene TherapyOncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006 Dec; 14(6):789-97.Mol Ther2006-10-10T00:00:002006Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.21558403Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci GClinical cancer research : an official journal of the American Association for Cancer ResearchDistinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clin Cancer Res. 2011 Jul 01; 17(13):4484-93.Clin Cancer Res2011-05-10T00:00:002011Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.Todo T, Ebright MI, Fong Y, Rabkin SD.Maruta H. editor. Tumor suppressing viruses, genes, and drugsOncolytic herpes simplex virus (G207) therapy: from basic to clinical. Maruta H. editor. Tumor suppressing viruses, genes, and drugs. 2002; 45-76.2002-01-01T00:00:002002Oncolytic herpes simplex virus (G207) therapy: from basic to clinical8542428Wood MJ, Byrnes AP, Rabkin SD, Pfaff DW, Charlton HMGene therapyImmunological consequences of HSV-1-mediated gene transfer into the CNS. Gene Ther. 1994; 1 Suppl 1:S82.Gene Ther1994-01-01T00:00:001994Immunological consequences of HSV-1-mediated gene transfer into the CNS.17908985Liu TC, Wakimoto H, Martuza RL, Rabkin SDClinical cancer research : an official journal of the American Association for Cancer ResearchHerpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res. 2007 Oct 01; 13(19):5897-902.Clin Cancer Res2007-10-01T00:00:002007Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.Authorship 1048673Authorship 10680211029793956Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SDJournal of virologyRestriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of ?34.5 in Glioblastoma Stem-Like Cells. J Virol. 2018 08 01; 92(15).J Virol2018-07-17T00:00:002018Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of ?34.5 in Glioblastoma Stem-Like Cells.22345479Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SDJournal of virologyEffect of ?34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol. 2012 Apr; 86(8):4420-31.J Virol2012-02-15T00:00:002012Effect of ?34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.16409122Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XOHuman gene therapyTreatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther. 2006 Jan; 17(1):20-30.Hum Gene Ther2006-01-01T00:00:002006Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.1519354Clarke P, Rabkin SD, Inman MV, Mahalingam R, Cohrs R, Wellish M, Gilden DHVirologyMolecular analysis of simian varicella virus DNA. Virology. 1992 Oct; 190(2):597-605.Virology1992-10-01T00:00:001992Molecular analysis of simian varicella virus DNA.1660157Rabkin SD, Hanlon BProceedings of the National Academy of Sciences of the United States of AmericaNucleoprotein complex formed between herpes simplex virus UL9 protein and the origin of DNA replication: inter- and intramolecular interactions. Proc Natl Acad Sci U S A. 1991 Dec 01; 88(23):10946-50.Proc Natl Acad Sci U S A1991-12-01T00:00:001991Nucleoprotein complex formed between herpes simplex virus UL9 protein and the origin of DNA replication: inter- and intramolecular interactions.23246627Murphy AM, Rabkin SDTranslational research : the journal of laboratory and clinical medicineCurrent status of gene therapy for brain tumors. Transl Res. 2013 Apr; 161(4):339-54.Transl Res2012-12-11T00:00:002012Current status of gene therapy for brain tumors.Rabkin S, Shtram Y, Becker Y. Becker Y. editor. Herpesvirus DNAReplication of HSV-1 DNA: Isolation of a subnuclear DNA synthesizing fraction. Becker Y. editor. Herpesvirus DNA. 1981; 95-106.1981-01-01T00:00:001981Replication of HSV-1 DNA: Isolation of a subnuclear DNA synthesizing fractionToda M, Uyemura K, Kawase T, Rabkin SD, Martuza RL.Uyemura K, Kawamura K, Yazaki T. editors. Neural Development. Treatment of metastatic brain tumors with a replication-competent multimutated herpes simplex virus-1. Uyemura K, Kawamura K, Yazaki T. editors. Neural Development. 1998; 521-525.1998-01-01T00:00:001998Treatment of metastatic brain tumors with a replication-competent multimutated herpes simplex virus-1Richardson CC, Beauchamp BB, Huber HE, Ikeda RA, Myers JA, Nakai H, Rabkin SD, Tabor S, White J.McMacken R, Kelly TJ. editors. DNA Replication and Recombination.
Bacteriophage T7 DNA replication. McMacken R, Kelly TJ. editors. DNA Replication and Recombination.
. 1987; 47:151-171.1987-01-01T00:00:001987Bacteriophage T7 DNA replication7585498Yazaki T, Manz HJ, Rabkin SD, Martuza RLCancer researchTreatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995 Nov 01; 55(21):4752-6.Cancer Res1995-11-01T00:00:001995Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.23197811Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RLStem cells translational medicineOncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012 Apr; 1(4):322-32.Stem Cells Transl Med2012-03-21T00:00:002012Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.30008259Saha D, Martuza RL, Rabkin SDImmunotherapyOncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy. 2018 07; 10(9):779-786.Immunotherapy2018-07-01T00:00:002018Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.Authorship 1079461321695156Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner VF, Rabkin SD, Demestre MPloS oneCancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS One. 2011; 6(6):e21099.PLoS One2011-06-13T00:00:002011Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.22898897Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin SD, Liu RCancer gene therapyTreatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012 Oct; 19(10):707-14.Cancer Gene Ther2012-08-17T00:00:002012Treatment of breast cancer stem cells with oncolytic herpes simplex virus.Moore PD, Rabkin SD, Strauss BS.Lemontt JF, Generoso WM. editors. Molecular and Cellular Mechanisms of MutagenesisIn vitro replication of mutagen-damaged DNA: Sites of termination. Lemontt JF, Generoso WM. editors. Molecular and Cellular Mechanisms of Mutagenesis. 1982; 179-197.1982-01-01T00:00:001982In vitro replication of mutagen-damaged DNA: Sites of terminationHunter W, Rabkin S, Martuza R.Kaplitt M, Loewy A. editors. Viral VectorsBrain tumor therapy using genetically engineered replication-competent virus. Kaplitt M, Loewy A. editors. Viral Vectors. 1995; 259-274.1995-01-01T00:00:001995Brain tumor therapy using genetically engineered replication-competent virus8738167New KC, Rabkin SDBrain research. Molecular brain researchCo-expression of two gene products in the CNS using double-cassette defective herpes simplex virus vectors. Brain Res Mol Brain Res. 1996 Apr; 37(1-2):317-23.Brain Res Mol Brain Res1996-04-01T00:00:001996Co-expression of two gene products in the CNS using double-cassette defective herpes simplex virus vectors.19197321Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RLCancer gene therapyOncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther. 2009 Jul; 16(7):551-60.Cancer Gene Ther2009-02-06T00:00:002009Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.21505062Kanai R, Wakimoto H, Martuza RL, Rabkin SDClinical cancer research : an official journal of the American Association for Cancer ResearchA novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 01; 17(11):3686-96.Clin Cancer Res2011-04-19T00:00:002011A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.Kaplitt, M., Rabkin, S. D. and Pfaff, D. W.Curr Top NeuroendocrinMolecular alterations in nerve cells: Direct manipulation and physiological mediation. Curr Top Neuroendocrin. 1992; 11:169-191.1992-01-01T00:00:001992Molecular alterations in nerve cells: Direct manipulation and physiological mediationRabkin S, Becker Y.Becker Y. editor. Herpesvirus DNA Biosynthesis of defective HSV DNA. Becker Y. editor. Herpesvirus DNA. 1981; 185-195.1981-01-01T00:00:001981Biosynthesis of defective HSV DNAAuthorship 117092219618115Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD, Gao G, Sena-Esteves MJournal of neuro-oncologyDirected evolution of adeno-associated virus for glioma cell transduction. J Neurooncol. 2010 Feb; 96(3):337-47.J Neurooncol2009-07-19T00:00:002009Directed evolution of adeno-associated virus for glioma cell transduction.HLK9HowardKaufmanHoward L. Kaufman, M.D.172901Kaufman, HowardLecturer on Surgery, Part-time4064014Strauss BS, Larson K, Sagher D, Rabkin S, Shenkar R, Sahm JCarcinogenesis; a comprehensive surveyIn vitro models of mutagenesis. Carcinog Compr Surv. 1985; 10:481-93.Carcinog Compr Surv1985-01-01T00:00:001985In vitro models of mutagenesis.7964989Kaplitt MG, Tjuvajev JG, Leib DA, Berk J, Pettigrew KD, Posner JB, Pfaff DW, Rabkin SD, Blasberg RGJournal of neuro-oncologyMutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol. 1994; 19(2):137-47.J Neurooncol1994-01-01T00:00:001994Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.15701824Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GH, Neuwelt EAClinical cancer research : an official journal of the American Association for Cancer ResearchNew frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):421-8.Clin Cancer Res2005-01-15T00:00:002005New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.17380741Aghi M, Rabkin S, Martuza RLClinical neurosurgeryOncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clin Neurosurg. 2006; 53:65-76.Clin Neurosurg2006-01-01T00:00:002006Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.Johnson P, Martuza R, Rabkin SD, Todo T, inventorsViral vectors and their use in therapeutic methodsViral vectors and their use in therapeutic methods. 2002.2002-10-03T00:00:002002Viral vectors and their use in therapeutic methods8542425New KC, Martuza RL, Rabkin SDGene therapyDefective herpes simplex virus vectors for the study of promoter and gene function in the CNS. Gene Ther. 1994; 1 Suppl 1:S79.Gene Ther1994-01-01T00:00:001994Defective herpes simplex virus vectors for the study of promoter and gene function in the CNS.8700129Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RIMolecular pharmacologyTreatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol. 1996 Aug; 50(2):236-42.Mol Pharmacol1996-08-01T00:00:001996Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.Authorship 127349221976549Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RLClinical cancer research : an official journal of the American Association for Cancer ResearchEnhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011 Dec 01; 17(23):7383-93.Clin Cancer Res2011-10-05T00:00:002011Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.Todo T, Rabkin SD.Curiel DT, Douglas JT. editors. Cancer Gene TherapyDevelopment of oncolytic replication-competent herpes simplex virus vectors. The G207 paradigm. Curiel DT, Douglas JT. editors. Cancer Gene Therapy. 2004; 199-210.2004-01-01T00:00:002004Development of oncolytic replication-competent herpes simplex virus vectors. The G207 paradigm11306480Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SDCancer researchBiological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 2001 Apr 01; 61(7):3009-15.Cancer Res2001-04-01T00:00:002001Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation.Martuza RL, Rabkin SD, Miyatake S-I, inventorsTissue or cell-specific herpes simplex virus replicationTissue or cell-specific herpes simplex virus replication. 2004.2004-08-25T00:00:002004Tissue or cell-specific herpes simplex virus replicationHunter W, Yazaki T, Rabkin S, Martuza R.Lowenstein P, Enquist L. editors. Protocols for Gene Transfer in Neuroscience: towards gene therapy of neurological disordersReplication-competent viral therapy of tumors in the central nervous system. Lowenstein P, Enquist L. editors. Protocols for Gene Transfer in Neuroscience: towards gene therapy of neurological disorders. 1996; 305-317.1996-01-01T00:00:001996Replication-competent viral therapy of tumors in the central nervous system6492159Rabkin SD, Strauss BSJournal of molecular biologyA role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts. J Mol Biol. 1984 Sep 25; 178(3):569-94.J Mol Biol1984-09-25T00:00:001984A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts.7542695Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RLJournal of neuro-oncologyInhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol. 1995; 23(1):23-9.J Neurooncol1995-01-01T00:00:001995Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.6448988Moore PD, Rabkin SD, Strauss BSNucleic acids researchTermination of vitro DNA synthesis at AAF adducts in the DNA. Nucleic Acids Res. 1980 Oct 10; 8(19):4473-84.Nucleic Acids Res1980-10-10T00:00:001980Termination of vitro DNA synthesis at AAF adducts in the DNA.19912815Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DWMolecular and cellular neurosciencesExpression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci. 1991 Aug; 2(4):320-30.Mol Cell Neurosci1991-08-01T00:00:001991Expression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vector.Friedman A, Rabkin S, Becker Y.Becker Y. editor. Herpesvirus DNAElectron microscopy of branched HSV DNA molecules: Possible recombination intermediates. Becker Y. editor. Herpesvirus DNA. 1981; 85-93.1981-01-01T00:00:001981Electron microscopy of branched HSV DNA molecules: Possible recombination intermediatesRabkin SDBiosynthesis of herpes simplex virus defective and wild-type DNA in vivo and in subnuclear fractionsBiosynthesis of herpes simplex virus defective and wild-type DNA in vivo and in subnuclear fractions. 1980.1980-01-01T00:00:001980Biosynthesis of herpes simplex virus defective and wild-type DNA in vivo and in subnuclear fractions6214248Moore PD, Rabkin SD, Strauss BSBasic life sciencesIn vitro replication of mutagen-damaged DNA: sites of termination. Basic Life Sci. 1982; 20:179-97.Basic Life Sci1982-01-01T00:00:001982In vitro replication of mutagen-damaged DNA: sites of termination.9188579Miyatake S, Iyer A, Martuza RL, Rabkin SDJournal of virologyTranscriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997 Jul; 71(7):5124-32.J Virol1997-07-01T00:00:001997Transcriptional targeting of herpes simplex virus for cell-specific replication.10516725Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza RGene therapyEffect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999 Oct; 6(10):1751-8.Gene Ther1999-10-01T00:00:001999Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.11387063Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RLHuman gene therapyPreclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther. 2001 May 20; 12(8):999-1010.Hum Gene Ther2001-05-20T00:00:002001Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates.16675589Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RLClinical cancer research : an official journal of the American Association for Cancer ResearchSystemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res. 2006 May 01; 12(9):2919-27.Clin Cancer Res2006-05-01T00:00:002006Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.17234749Aghi M, Rabkin SD, Martuza RLCancer researchAngiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 2007 Jan 15; 67(2):440-4.Cancer Res2007-01-15T00:00:002007Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.17304235Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XOCancer gene therapyTreatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007 May; 14(5):460-7.Cancer Gene Ther2007-02-16T00:00:002007Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.Authorship 1126341830644426Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto HScientific reportsGenetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.Sci Rep2019-01-15T00:00:002019Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.7585221Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RLNature medicineAttenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995 Sep; 1(9):938-43.Nat Med1995-09-01T00:00:001995Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.Authorship 1289984D050504Living Beings1033210.728917Oncolytic VirusesAuthorship 11449964Authorship 1142932230541787Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HLScience translational medicineMEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 2018 12 12; 10(471).Sci Transl Med2018-12-12T00:00:002018MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.30906668Bommareddy PK, Rabkin SD, Kaufman HLOncoimmunologyTriple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology. 2019; 8(4):e1571390.Oncoimmunology2019-02-03T00:00:002019Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade.D050130Procedures1394890.648857Oncolytic VirotherapyD018139Living Beings1888040.732053SimplexvirusD005909Disorders78834310.332312GlioblastomaD005822Chemicals & DrugsLiving Beings104134190.483301Genetic VectorsAuthorship 1149430731016228Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD, Martuza RLMolecular therapy oncolyticsOncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Mol Ther Oncolytics. 2019 Jun 28; 13:58-66.Mol Ther Oncolytics2019-03-29T00:00:002019Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.Authorship 1208823GeneticsNeurologyPsychiatrySurgeryBrigham and Women's HospitalDana-Farber Cancer InstituteMassachusetts General HospitalAuthorship 1337725HW2HiroakiWakimotoHiroaki Wakimoto, M.D., Ph.D.42.36125700000000-71.0655270000000055945Wakimoto, HiroakiAssociate Professor of NeurosurgeryPYW1PatrickWenPatrick Yung Chih Wen, M.D.42.33789600000000-71.1072493000000022271Wen, PatrickProfessor of NeurologyAuthorship 1156274431123687Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha DJournal of biological methodsMulti-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods. 2019; 6(2).J Biol Methods2019-04-04T00:00:002019Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.MPF10MarleneFreemanMarlene P Freeman, M.D.42.36125700000000-71.0655270000000069291Freeman, MarleneProfessor of PsychiatryAuthorship 1157923331143509Bommareddy PK, Zloza A, Rabkin SD, Kaufman HLOncoimmunologyOncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology. 2019; 8(7):1591875.Oncoimmunology2019-04-07T00:00:002019Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.RLM4RobertMartuzaRobert Lawrence Martuza, M.D.42.36435790000000-71.0661193000000035515Martuza, RobertWilliam and Elizabeth Sweet Distinguished Professor of Neuroscience in the Department of NeurosurgeryYG48YuliaGrishchukYulia Grishchuk, Ph.D.42.36125700000000-71.0655270000000024435Grishchuk, YuliaAssistant Professor of Neurology11189selected publications8.591070.00105368541research areas6.667380.0026402838coauthor of289.01617.884160similar toAuthorship 1528476EAC4E.ChioccaE. Antonio Chiocca, M.D.,Ph.D.53734Chiocca, E.Harvey W. Cushing Professor of NeurosurgeryJFG2JamesGusellaJames Francis Gusella, Ph.D.42.36125700000000-71.0655270000000078528Gusella, JamesBullard Professor of Neurogenetics in the Department of GeneticsAuthorship 116858414Authorship 11666681131253799Wu MR, Nissim L, Stupp D, Pery E, Binder-Nissim A, Weisinger K, Enghuus C, Palacios SR, Humphrey M, Zhang Z, Maria Novoa E, Kellis M, Weiss R, Rabkin SD, Tabach Y, Lu TKNature communicationsA high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nat Commun. 2019 06 28; 10(1):2880.Nat Commun2019-06-28T00:00:002019A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS).31266951Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, Lees J, Zou L, Martuza RL, Wakimoto H, Rabkin SDNature communicationsMyc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019 07 02; 10(1):2910.Nat Commun2019-07-02T00:00:002019Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.BS13BrianSeedBrian Seed, Ph.D.42.36125700000000-71.0655270000000012983Seed, BrianProfessor of GeneticsAuthorship 1172126931301014Nigim F, Kiyokawa J, Gurtner A, Kawamura Y, Hua L, Kasper EM, Brastianos PK, Cahill DP, Rabkin SD, Martuza RL, Carbonell WS, Wakimoto HTargeted oncologyA Monoclonal Antibody Against ß1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Target Oncol. 2019 08; 14(4):479-489.Target Oncol2019-08-01T00:00:002019A Monoclonal Antibody Against ß1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.Authorship 1187405231486038Saha D, Rabkin SDMethods in molecular biology (Clifton, N.J.)Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy. Methods Mol Biol. 2020; 2058:179-190.Methods Mol Biol2020-01-01T00:00:002020Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.Authorship 1574922true1William and Elizabeth Sweet Distinguished Professor of Neuroscience in the Department of NeurosurgeryWilliam and Elizabeth Sweet Distinguished Professor of Neuroscience in the Department of Neurosurgerytrue1Thomas A. Pappas Professor of NeurosciencesThomas A. Pappas Professor of Neurosciencestrue1Lecturer on Surgery, Part-timeLecturer on Surgery, Part-timetrue1Associate Professor of NeurosurgeryAssociate Professor of Neurosurgerytrue1Professor of NeurologyProfessor of Neurologytrue1Bullard Professor of Neurogenetics in the Department of GeneticsBullard Professor of Neurogenetics in the Department of GeneticsAuthorship 1374263Authorship 1311297Authorship 1648801true1Professor of PsychiatryProfessor of PsychiatryAuthorship 1250454232457126Saha D, Rabkin SD, Martuza RLJournal for immunotherapy of cancerTemozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020 05; 8(1).J Immunother Cancer2020-05-01T00:00:002020Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.Authorship 1411565Authorship 1475532true1Assistant Professor of NeurologyAssistant Professor of NeurologyAuthorship 1305780233232188Zhang S, Rabkin SDExpert opinion on drug discoveryThe discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert Opin Drug Discov. 2021 04; 16(4):391-410.Expert Opin Drug Discov2020-12-14T00:00:002020The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?Authorship 1308373933257429Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçin E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto HClinical cancer research : an official journal of the American Association for Cancer ResearchModification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 02 01; 27(3):889-902.Clin Cancer Res2020-11-30T00:00:002020Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.Authorship 213889233308315Li M, Li G, Kiyokawa J, Tirmizi Z, Richardson LG, Ning J, Das S, Martuza RL, Stemmer-Rachamimov A, Rabkin SD, Wakimoto HActa neuropathologica communicationsCharacterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathol Commun. 2020 12 11; 8(1):221.Acta Neuropathol Commun2020-12-11T00:00:002020Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.Authorship 131067510Authorship 2131081Authorship 1360454434057449Nguyen HM, Sah N, Humphrey MRM, Rabkin SD, Saha DJournal of visualized experiments : JoVEGrowth, Purification, and Titration of Oncolytic Herpes Simplex Virus. J Vis Exp. 2021 05 13; (171).J Vis Exp2021-05-13T00:00:002021Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus.Authorship 1398694434578321Jahan N, Ghouse SM, Martuza RL, Rabkin SDVirusesIn Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses. 2021 08 31; 13(9).Viruses2021-08-31T00:00:002021In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.Authorship 2052195kik394KimiaKardaniKimia Kardani, Ph.D.203469Kardani, KimiaResearch Fellow in Neurosurgery2024-05-31T00:00:002021-01-18T00:00:00Oncolytic herpes simplex viruses for the treatment of brain tumors<p>Research opportunities (in-person participation) for medical students, preferably with some laboratory-based research experience, in the Brain Tumor Research Center, Simches Research Building, MGH.</p> <p>Our laboratory focuses on the use of oncolytic herpes simplex virus (oHSV) vectors for cancer therapy of brain tumors, especially glioblastoma. A number of different vector strategies are being developed: (i) oHSV vectors mutated in different viral genes to target the cancer cell phenotype due to physiologic/signaling pathway differences with 'normal' cells; (ii) recombinant oHSV vectors expressing therapeutic transgenes; and (iii) transcriptionally-regulated oHSV vectors that are targeted by cancer-specific gene expression. These vectors are characterized in a range of tumor models; human tumor xenografts in nude mice, mouse tumors in immunocompetent mice, and cancer stem cells.</p> <p>We are exploring a number of therapeutic oHSV strategies: (i) synergistic combinations with chemotherapeutics and molecularly targeted drugs; (ii) targeting the tumor microenvironment using 'armed' oHSV; and (iii) immunotherapy approaches, including combinations with immune modulatory agents.</p>Authorship 2994146jug476JuditSanchez GilJudit Sanchez Gil, Ph.D.209170Sanchez Gil, JuditResearch Fellow in NeurosurgeryAuthorship 3911134Authorship 1493755936271587Kawamura Y, Hua L, Gurtner A, Wong E, Kiyokawa J, Shah N, Gorham J, Wakimoto H, Rabkin SD, Martuza RL, Wakimoto HBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieHistone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. Biomed Pharmacother. 2022 Nov; 155:113843.Biomed Pharmacother2022-10-08T00:00:002022Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma.Authorship 1503735236396753Sanchez Gil J, Rabkin SDNature cancerAn armed oncolytic virus for GBM Destruction. Nat Cancer. 2022 Nov; 3(11):1274-1276.Nat Cancer2022-11-01T00:00:002022An armed oncolytic virus for GBM Destruction.Authorship 1967944Authorship 2223253Authorship 2090854Authorship 1561883337325516Kardani K, Sanchez Gil J, Rabkin SDFrontiers in cellular and infection microbiologyOncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells. Front Cell Infect Microbiol. 2023; 13:1206111.Front Cell Infect Microbiol2023-05-31T00:00:002023Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.Authorship 2236431Authorship 3365484Authorship 15847667Authorship 15855001237578106Wang H, Borlongan M, Hemminki A, Basnet S, Sah N, Kaufman HL, Rabkin SD, Saha DHuman gene therapyViral Vectors Expressing Interleukin 2 for Cancer Immunotherapy. Hum Gene Ther. 2023 09; 34(17-18):878-895.Hum Gene Ther2023-09-01T00:00:002023Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.37619813Shimizu K, Kahramanian A, Jabbar MADA, Turna Demir F, Gokyer D, Uthamacumaran A, Rajan A, Saad MA, Gorham J, Wakimoto H, Martuza RL, Rabkin SD, Hasan T, Wakimoto HCancer lettersPhotodynamic augmentation of oncolytic virus therapy for central nervous system malignancies. Cancer Lett. 2023 09 28; 572:216363.Cancer Lett2023-08-22T00:00:002023Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.true1Research Fellow in NeurosurgeryResearch Fellow in Neurosurgerytrue1Professor of GeneticsProfessor of Geneticstrue1Harvey W. Cushing Professor of NeurosurgeryHarvey W. Cushing Professor of Neurosurgerytrue1Research Fellow in NeurosurgeryResearch Fellow in NeurosurgeryAuthorship 44615822025-09-30T00:00:002024-01-16T00:00:00Characterization of novel oncolytic herpes simplex virusesWe are developing oncolytic herpes simplex viruses (oHSVs) for cancer therapy, in particular for glioblastoma. We have isolated a spontaneously arising 'large plaque' mutant of oHSV. This mutant needs to be characterized in depth, both in vitro and in vivo. This includes bioinformatic analysis of genome sequences and RNA expression in infected cells to identify the sequence alterations responsible for the phenotype and the mechanism of action. In vitro, the biology of the mutant and its impact on cancer and normal cells will be studied. In vivo, the efficacy of the mutant in glioblastoma stem-like cell tumor models, human and mouse, that we have developed, and its 'safety' will be determined.Authorship 5655852Authorship 598358Authorship 1687075Authorship 4304073Authorship 4582552Authorship 3285062Authorship 6510058Authorship 6632878Authorship 661408823754388Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SDProceedings of the National Academy of Sciences of the United States of AmericaMultifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):12006-11.Proc Natl Acad Sci U S A2013-06-10T00:00:002013Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.23707066Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BECell reportsAn aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30; 3(5):1567-79.Cell Rep2013-05-23T00:00:002013An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.23730207Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RLNeoplasia (New York, N.Y.)Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013 Jun; 15(6):591-9.Neoplasia2013-06-01T00:00:002013Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Authorship 1991242Authorship 2955494NeurosurgeryAuthorship 2244283Authorship 2203452Authorship 2432622Authorship 627532Authorship 3062072Authorship 2007165Authorship 714949324241205Ning J, Wakimoto H, Rabkin SDCell cycle (Georgetown, Tex.)Immunovirotherapy for glioblastoma. Cell Cycle. 2014; 13(2):175-6.Cell Cycle2013-11-14T00:00:002013Immunovirotherapy for glioblastoma.24470552Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SDNeuro-oncologyTreatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 2014 Aug; 16(8):1057-66.Neuro Oncol2014-01-26T00:00:002014Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Authorship 7270356Authorship 727204224726434Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BECellReconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24; 157(3):580-94.Cell2014-04-10T00:00:002014Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.24764576Chiocca EA, Rabkin SDCancer immunology researchOncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014 Apr; 2(4):295-300.Cancer Immunol Res2014-04-01T00:00:002014Oncolytic viruses and their application to cancer immunotherapy.Authorship 1980578Authorship 3277026Authorship 2082303Authorship 7439837Authorship 3815674Authorship 3195648Authorship 2693622Authorship 3604633Authorship 756122223687568Kanai R, Rabkin SDCNS oncologyCombinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol. 2013 Mar; 2(2):129-42.CNS Oncol2013-03-01T00:00:002013Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Authorship 582329Authorship 767185625360068Wang J, Xu L, Zeng W, Hu P, Zeng M, Rabkin SD, Liu RCancer cell internationalTreatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int. 2014; 14(1):83.Cancer Cell Int2014-09-19T00:00:002014Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.Authorship 4798855Authorship 5016294Authorship 496212225213669Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto HJournal of neuro-oncologySingle agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. 2015 Jan; 121(1):91-100.J Neurooncol2014-09-12T00:00:002014Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.Authorship 5679325Authorship 2558934Authorship 3167864Authorship 3178572Authorship 616517Authorship 977002Authorship 3329289Authorship 4815763Authorship 1617993Authorship 5120915Authorship 3104833Authorship 5368381Authorship 55575Authorship 587307Authorship 588774Authorship 596343Authorship 592267Authorship 1879058Authorship 234111Authorship 626201Authorship 629126Authorship 2415644Authorship 2841221Authorship 1822072Authorship 18377410Authorship 3189208Authorship 2984005Authorship 3042142Authorship 3122510Authorship 3722312Authorship 3845194Authorship 4081472Authorship 490634Authorship 518036Authorship 2297897Authorship 2086133Authorship 2623483Authorship 23811215Authorship 847123Authorship 3709212Authorship 4414534Authorship 283862Authorship 23392915Authorship 2853946Authorship 37666111Authorship 4830752Authorship 5475374Authorship 7925564Authorship 793057525735362Wang JN, Xu LH, Zeng WG, Hu P, Rabkin SD, Liu RRAsian Pacific journal of cancer prevention : APJCPTreatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus. Asian Pac J Cancer Prev. 2015; 16(3):1241-5.Asian Pac J Cancer Prev2015-01-01T00:00:002015Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.Authorship 36146Authorship 433174Authorship 4336588Authorship 4024442Authorship 8117701026083570Nigim F, Cavanaugh J, Patel AP, Curry WT, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto HJournal of neuropathology and experimental neurologyTargeting Hypoxia-Inducible Factor 1a in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol. 2015 Jul; 74(7):710-22.J Neuropathol Exp Neurol2015-07-01T00:00:002015Targeting Hypoxia-Inducible Factor 1a in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.Authorship 5579314Authorship 586280Authorship 592273Authorship 38395012Authorship 595106Authorship 852932Authorship 9990332007-08-03T00:00:002007-04-02T00:00:00Infection Study of Human Neural Stem Cells with Oncolytic HSVSummerAuthorship 4958986Authorship 880882227186404Esaki S, Rabkin SD, Martuza RL, Wakimoto HAmerican journal of cancer researchTransient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016; 6(2):300-11.Am J Cancer Res2016-01-15T00:00:002016Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.Authorship 5526891Authorship 611829Authorship 897503Authorship 55825942Assistant Professor1Associate Professor6Fellow or Post Doc0Full Professor3LecturerAuthorship 622760Authorship 677997Authorship 801367Authorship 600302Authorship 579765Authorship 604318Authorship 612882Authorship 621843Authorship 4991127Authorship 9089661026951380Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto HNeuro-oncologyA new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016 09; 18(9):1278-87.Neuro Oncol2016-03-06T00:00:002016A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.Authorship 5630652Authorship 597698Authorship 5983912005-04-30RABKIN, SAMUEL D1994-08-01GENE DELIVERY TO THE CNS TO MODULATE EPILEPSYR01NS0333422019-05-31BREAKEFIELD, XANDRA OWENS2003-05-01Interdepartmental Neuroscience CenterP30NS0457762015-06-30RABKIN, SAMUEL DAVID2012-07-20Selective Differentiation of Glioblastoma Stem CellsR21CA1647262024-01-31RABKIN, SAMUEL DAVID2012-05-03Targeting tumorigenic pathways in glioblastoma with oncolytic HSVR01CA160762Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorCo-Principal InvestigatorAuthorship 623707185 Cambridge StMassachusetts General HospitalBrain Tumor Research Ctr, Simches, CPZN-3800185 Cambridge StBoston02114MAAuthorship 3688072Authorship 9204092Authorship 924205424575383Cheema TA, Fecci PE, Ning J, Rabkin SDOncoimmunologyImmunovirotherapy for the treatment of glioblastoma. Oncoimmunology. 2014 Jan 01; 3(1):e27218.Oncoimmunology2014-01-01T00:00:002014Immunovirotherapy for the treatment of glioblastoma.26462293Peters C, Rabkin SDMolecular therapy oncolyticsDesigning Herpes Viruses as Oncolytics. Mol Ther Oncolytics. 2015; 2.Mol Ther Oncolytics2015-07-22T00:00:002015Designing Herpes Viruses as Oncolytics.Authorship 50984214Authorship 5280845Authorship 5381422Authorship 9328323Authorship 9331542Authorship 57846526855472Saha D, Ahmed SS, Rabkin SDDrugs of the futureEXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future. 2015; 40(11):739-749.Drugs Future2015-01-01T00:00:002015EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.27867771Antoszczyk S, Rabkin SDExpert opinion on orphan drugsProspect and progress of oncolytic viruses for treating peripheral nerve sheath tumors. Expert Opin Orphan Drugs. 2016; 4(2):129-138.Expert Opin Orphan Drugs2015-12-26T00:00:002015Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.Authorship 608969Authorship 833934Authorship 90943Authorship 1965821Authorship 2784203Authorship 2935813Authorship 3282443Authorship 610959Authorship 614088Authorship 62505010953167Jasmin L, Janni G, Ohara PT, Rabkin SDThe Journal of urologyCNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat. J Urol. 2000 Sep; 164(3 Pt 1):852-5.J Urol2000-09-01T00:00:002000CNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat.15740669Liu RB, Rabkin SDChinese medical journalOncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J (Engl). 2005 Feb 20; 118(4):307-12.Chin Med J (Engl)2005-02-20T00:00:002005Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.9037547Yazaki T, Martuza RL, Rabkin SDBrain research. Molecular brain researchExpression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration. Brain Res Mol Brain Res. 1996 Dec 31; 43(1-2):311-20.Brain Res Mol Brain Res1996-12-31T00:00:001996Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration.9574551Toda M, Martuza RL, Kojima H, Rabkin SDJournal of immunology (Baltimore, Md. : 1950)In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998 May 01; 160(9):4457-64.J Immunol1998-05-01T00:00:001998In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.10400723Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SDJournal of virologyAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999 Aug; 73(8):6319-26.J Virol1999-08-01T00:00:001999Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.15647762Liu R, Martuza RL, Rabkin SDGene therapyIntracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 2005 Apr; 12(8):647-54.Gene Ther2005-04-01T00:00:002005Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.Authorship 9626283Authorship 962715227497296Saha D, Wakimoto H, Rabkin SDCurrent opinion in virologyOncolytic herpes simplex virus interactions with the host immune system. Curr Opin Virol. 2016 12; 21:26-34.Curr Opin Virol2016-08-03T00:00:002016Oncolytic herpes simplex virus interactions with the host immune system.28184805Aghi MK, Rabkin S, Martuza RLNeurosurgery840 Enhanced Replication of Oncolytic Herpes Simplex Virus in Glioma Cells that Evade Temozolomide Chemotherapy through DNA Repair. Neurosurgery. 2005 Aug 01; 57(2):408-409.Neurosurgery2005-08-01T00:00:002005840 Enhanced Replication of Oncolytic Herpes Simplex Virus in Glioma Cells that Evade Temozolomide Chemotherapy through DNA Repair.9183657Rabkin SD, Mineta T, Miyatake S, Yazaki THuman cellGene therapy: targeting tumor cells for destruction. Hum Cell. 1996 Dec; 9(4):265-76.Hum Cell1996-12-01T00:00:001996Gene therapy: targeting tumor cells for destruction.10048391Toda M, Rabkin SD, Kojima H, Martuza RLHuman gene therapyHerpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10; 10(3):385-93.Hum Gene Ther1999-02-10T00:00:001999Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.9253507Miyatake S, Martuza RL, Rabkin SDCancer gene therapyDefective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997 Jul-Aug; 4(4):222-8.Cancer Gene Ther1997-07-01T00:00:001997Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.9822756Jasmin L, Janni G, Manz HJ, Rabkin SDThe Journal of neuroscience : the official journal of the Society for NeuroscienceActivation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. J Neurosci. 1998 Dec 01; 18(23):10016-29.J Neurosci1998-12-01T00:00:001998Activation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation.10729157Sundaresan P, Hunter WD, Martuza RL, Rabkin SDJournal of virologyAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol. 2000 Apr; 74(8):3832-41.J Virol2000-04-01T00:00:002000Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.10845725Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RLGene therapyConditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000 May; 7(10):867-74.Gene Ther2000-05-01T00:00:002000Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.17613221Jeyaretna DS, Rabkin SD, Martuza RLNeurosurgical focusOncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg Focus. 2007 Jun 15; 22(6):E4.Neurosurg Focus2007-06-15T00:00:002007Oncolytic herpes simplex virus therapy for peripheral nerve tumors.17909046Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RLCancer researchSystemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007 Oct 01; 67(19):9371-9.Cancer Res2007-10-01T00:00:002007Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.19440231Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, Pikarsky E, Rabkin SD, Panet A, Zamir GGene therapyHerpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther. 2009 Jul; 16(7):905-15.Gene Ther2009-05-14T00:00:002009Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.Authorship 975387528376211Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SDJournal of the National Cancer InstituteRad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. J Natl Cancer Inst. 2017 03 01; 109(3):1-13.J Natl Cancer Inst2017-03-01T00:00:002017Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.229801Becker Y, Gutter B, Cohen Y, Chejanovsky N, Rabkin S, Fridlender BArchives of virologyHerpes simplex virus DNA polymerase, thymidine kinase and deoxyribonuclease activities in cells infected with wild type, ultraviolet-irradiated and defective virus. Arch Virol. 1979; 62(3):163-74.Arch Virol1979-01-01T00:00:001979Herpes simplex virus DNA polymerase, thymidine kinase and deoxyribonuclease activities in cells infected with wild type, ultraviolet-irradiated and defective virus.9795182New KC, Gale K, Martuza RL, Rabkin SDBrain research. Molecular brain researchNovel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. Brain Res Mol Brain Res. 1998 Oct 30; 61(1-2):121-35.Brain Res Mol Brain Res1998-10-30T00:00:001998Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase.12522436Varghese S, Rabkin SDCancer gene therapyOncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002 Dec; 9(12):967-78.Cancer Gene Ther2002-12-01T00:00:002002Oncolytic herpes simplex virus vectors for cancer virotherapy.15735042Liu R, Varghese S, Rabkin SDCancer researchOncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2005 Feb 15; 65(4):1532-40.Cancer Res2005-02-15T00:00:002005Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.11687957Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RLNeoplasia (New York, N.Y.)Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001 Sep-Oct; 3(5):451-6.Neoplasia2001-09-01T00:00:002001Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.9794202Toda M, Rabkin SD, Martuza RLHuman gene therapyTreatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998 Oct 10; 9(15):2177-85.Hum Gene Ther1998-10-10T00:00:001998Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.10498254Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RLHuman gene therapyLocal and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther. 1999 Sep 01; 10(13):2237-43.Hum Gene Ther1999-09-01T00:00:001999Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.10908608Moulding HD, Martuza RL, Rabkin SDThe Journal of neuroscience : the official journal of the Society for NeuroscienceClinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression. J Neurosci. 2000 Aug 01; 20(15):5696-702.J Neurosci2000-08-01T00:00:002000Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression.20373873Kanai R, Wakimoto H, Cheema T, Rabkin SDFuture oncology (London, England)Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol. 2010 Apr; 6(4):619-34.Future Oncol2010-04-01T00:00:002010Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?16391370Aghi M, Rabkin S, Martuza RLJournal of the National Cancer InstituteEffect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst. 2006 Jan 04; 98(1):38-50.J Natl Cancer Inst2006-01-04T00:00:002006Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.16995942Kuroda T, Martuza RL, Todo T, Rabkin SDBMC biotechnologyFlip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol. 2006 Sep 22; 6:40.BMC Biotechnol2006-09-22T00:00:002006Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.17047077Kuroda T, Rabkin SD, Martuza RLCancer researchEffective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. 2006 Oct 15; 66(20):10127-35.Cancer Res2006-10-15T00:00:002006Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.17121900Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SDClinical cancer research : an official journal of the American Association for Cancer ResearchDominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res. 2006 Nov 15; 12(22):6791-9.Clin Cancer Res2006-11-15T00:00:002006Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.18957963Aghi MK, Liu TC, Rabkin S, Martuza RLMolecular therapy : the journal of the American Society of Gene TherapyHypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther. 2009 Jan; 17(1):51-6.Mol Ther2008-10-28T00:00:002008Hypoxia enhances the replication of oncolytic herpes simplex virus.2168979Rabkin SD, Hanlon BJournal of virologyHerpes simplex virus DNA synthesis at a preformed replication fork in vitro. J Virol. 1990 Oct; 64(10):4957-67.J Virol1990-10-01T00:00:001990Herpes simplex virus DNA synthesis at a preformed replication fork in vitro.11353831Todo T, Martuza RL, Rabkin SD, Johnson PAProceedings of the National Academy of Sciences of the United States of AmericaOncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001 May 22; 98(11):6396-401.Proc Natl Acad Sci U S A2001-05-15T00:00:002001Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.20220784Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RLGene therapyOncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther. 2010 Jun; 17(6):805-10.Gene Ther2010-03-11T00:00:002010Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.Martuza R., Rabkin SD, Mineta T, inventorsReplication-competent herpes simplex virus mediates destruction of neoplastic cellsReplication-competent herpes simplex virus mediates destruction of neoplastic cells. 2000.2000-10-31T00:00:002000Replication-competent herpes simplex virus mediates destruction of neoplastic cells16179929Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RLCancer gene therapyEnhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 2006 Mar; 13(3):253-65.Cancer Gene Ther2006-03-01T00:00:002006Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.6165985Moore PD, Bose KK, Rabkin SD, Strauss BSProceedings of the National Academy of Sciences of the United States of AmericaSites of termination of in vitro DNA synthesis on ultraviolet- and N-acetylaminofluorene-treated phi X174 templates by prokaryotic and eukaryotic DNA polymerases. Proc Natl Acad Sci U S A. 1981 Jan; 78(1):110-4.Proc Natl Acad Sci U S A1981-01-01T00:00:001981Sites of termination of in vitro DNA synthesis on ultraviolet- and N-acetylaminofluorene-treated phi X174 templates by prokaryotic and eukaryotic DNA polymerases.18988803Farassati F, Pan W, Yamoutpour F, Henke S, Piedra M, Frahm S, Al-Tawil S, Mangrum WI, Parada LF, Rabkin SD, Martuza RL, Kurtz AThe American journal of pathologyRas signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol. 2008 Dec; 173(6):1861-72.Am J Pathol2008-11-06T00:00:002008Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.7821388Wood MJ, Byrnes AP, Kaplitt MG, Pfaff DW, Rabkin SD, Charlton HMExperimental neurologySpecific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting. Exp Neurol. 1994 Nov; 130(1):127-40.Exp Neurol1994-11-01T00:00:001994Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting.8033122Mineta T, Rabkin SD, Martuza RLCancer researchTreatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994 Aug 01; 54(15):3963-6.Cancer Res1994-08-01T00:00:001994Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.9832128New KC, Rabkin SDJournal of neurochemistryGABA synthesis in astrocytes after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase 65 or 67. J Neurochem. 1998 Dec; 71(6):2304-12.J Neurochem1998-12-01T00:00:001998GABA synthesis in astrocytes after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase 65 or 67.11124059Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RLMolecular therapy : the journal of the American Society of Gene TherapyViral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther. 2000 Dec; 2(6):588-95.Mol Ther2000-12-01T00:00:002000Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.22067563Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SDNeuro-oncologyMaintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb; 14(2):132-44.Neuro Oncol2011-11-07T00:00:002011Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.3065520Rabkin SD, Richardson CCJournal of molecular biologyInitiation of DNA replication at cloned origins of bacteriophage T7. J Mol Biol. 1988 Dec 20; 204(4):903-16.J Mol Biol1988-12-20T00:00:001988Initiation of DNA replication at cloned origins of bacteriophage T7.Rabkin SDIn Vitro DNA synthesis on mutagen reacted templatesIn Vitro DNA synthesis on mutagen reacted templates. 1984.1984-01-01T00:00:001984In Vitro DNA synthesis on mutagen reacted templatesAuthorship 10054523Authorship 10045681128801914Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto HInternational journal of cancerBlockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358.Int J Cancer2017-08-26T00:00:002017Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.28810147Saha D, Martuza RL, Rabkin SDCancer cellMacrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell. 2017 08 14; 32(2):253-267.e5.Cancer Cell2017-08-14T00:00:002017Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.19693098Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RLGene therapyAnalysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther. 2009 Dec; 16(12):1477-82.Gene Ther2009-12-01T00:00:002009Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.8090756Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DWProceedings of the National Academy of Sciences of the United States of AmericaPreproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci U S A. 1994 Sep 13; 91(19):8979-83.Proc Natl Acad Sci U S A1994-09-13T00:00:001994Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector.11020347Toda M, Martuza RL, Rabkin SDMolecular therapy : the journal of the American Society of Gene TherapyTumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000 Oct; 2(4):324-9.Mol Ther2000-10-01T00:00:002000Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.11312559Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A, Chalavi AExperimental neurologyTherapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol. 2001 May; 169(1):64-71.Exp Neurol2001-05-01T00:00:002001Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.2305553Rabkin SD, Richardson CCVirologyIn vivo analysis of the initiation of bacteriophage T7 DNA replication. Virology. 1990 Feb; 174(2):585-92.Virology1990-02-01T00:00:001990In vivo analysis of the initiation of bacteriophage T7 DNA replication.28966936Saha D, Martuza RL, Rabkin SDOncoscienceCuring glioblastoma: oncolytic HSV-IL12 and checkpoint blockade. Oncoscience. 2017 Jul; 4(7-8):67-69.Oncoscience2017-09-20T00:00:002017Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.22653387Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WTNeurosurgeryExpression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep; 71(3):741-8; discussion 748.Neurosurgery2012-09-01T00:00:002012Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.Authorship 101690236215955Strauss B, Rabkin S, Sagher D, Moore PBiochimieThe role of DNA polymerase in base substitution mutagenesis on non-instructional templates. Biochimie. 1982 Aug-Sep; 64(8-9):829-38.Biochimie1982-08-01T00:00:001982The role of DNA polymerase in base substitution mutagenesis on non-instructional templates.7854056Verhaagen J, Hermens WT, Oestreicher AB, Gispen WH, Rabkin SD, Pfaff DW, Kaplitt MGBrain research. Molecular brain researchExpression of the growth-associated protein B-50/GAP43 via a defective herpes-simplex virus vector results in profound morphological changes in non-neuronal cells. Brain Res Mol Brain Res. 1994 Oct; 26(1-2):26-36.Brain Res Mol Brain Res1994-10-01T00:00:001994Expression of the growth-associated protein B-50/GAP43 via a defective herpes-simplex virus vector results in profound morphological changes in non-neuronal cells.10933051Chahlavi A, Todo T, Martuza RL, Rabkin SDNeoplasia (New York, N.Y.)Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999 Jun; 1(2):162-9.Neoplasia1999-06-01T00:00:001999Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.11313808Toda M, Martuza RL, Rabkin SDGene therapyCombination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001 Feb; 8(4):332-9.Gene Ther2001-02-01T00:00:002001Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.12867983Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PTNatureAnalgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex. Nature. 2003 Jul 17; 424(6946):316-20.Nature2003-07-17T00:00:002003Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex.2432007Strauss B, Larson K, Rabkin S, Sagher D, Sahm JIARC scientific publicationsTermination of synthesis resulting from modifying bases in DNA. IARC Sci Publ. 1986; (70):387-92.IARC Sci Publ1986-01-01T00:00:001986Termination of synthesis resulting from modifying bases in DNA.20424118Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RLCancer researchIdentification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 2010 May 15; 70(10):3890-5.Cancer Res2010-04-27T00:00:002010Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.21915104Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RLMolecular therapy : the journal of the American Society of Gene TherapyBevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther. 2012 Jan; 20(1):37-45.Mol Ther2011-09-13T00:00:002011Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Rabkin SD, Hernaiz Driever P.Rabkin SD, Hernaiz Driever P. editors. Replication-competent viruses for cancer therapy. Replication-competent herpes simplex virus vectors for cancer therapy. Rabkin SD, Hernaiz Driever P. editors. Replication-competent viruses for cancer therapy. 2001; 22:1-45.2001-01-01T00:00:002001Replication-competent herpes simplex virus vectors for cancer therapyRabkin SD, Toda M, Martuza RL, inventorsUse of herpes vectors for tumor therapyUse of herpes vectors for tumor therapy. 2002.2002-04-30T00:00:002002Use of herpes vectors for tumor therapyRabkin SD, Miyatake S, Martuza RL, inventorsTumor- or cell-specific herpes simplex virus replicationTumor- or cell-specific herpes simplex virus replication. 1998.1998-03-17T00:00:001998Tumor- or cell-specific herpes simplex virus replication16248277Aghi M, Rabkin SCurrent opinion in molecular therapeuticsViral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther. 2005 Oct; 7(5):419-30.Curr Opin Mol Ther2005-10-01T00:00:002005Viral vectors as therapeutic agents for glioblastoma.22173583Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RLJournal of the National Cancer InstituteOncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012 Jan 04; 104(1):42-55.J Natl Cancer Inst2011-12-15T00:00:002011Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.19047097Farrell CJ, Zaupa C, Barnard Z, Maley J, Martuza RL, Rabkin SD, Curry WTClinical cancer research : an official journal of the American Association for Cancer ResearchCombination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008 Dec 01; 14(23):7711-6.Clin Cancer Res2008-12-01T00:00:002008Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.Strauss BS, Larson K, Sagher D, Rabkin S, Shenkar R, Sahm J.Huberman E. editor. The Role of Chemicals and Radiation in the Etiology of Cancer. CarcinogenesisIn vitro models of mutagenesis. Huberman E. editor. The Role of Chemicals and Radiation in the Etiology of Cancer. Carcinogenesis. 1985; 10:481-509.1985-01-01T00:00:001985In vitro models of mutagenesis3529104Strauss B, Larson K, Rabkin S, Sagher D, Sahm J, Shenkar RProgress in clinical and biological researchIn vitro models for mutagenesis: a role for lesion, polymerase and sequence. Prog Clin Biol Res. 1986; 209A:149-59.Prog Clin Biol Res1986-01-01T00:00:001986In vitro models for mutagenesis: a role for lesion, polymerase and sequence.6340105Rabkin SD, Moore PD, Strauss BSProceedings of the National Academy of Sciences of the United States of AmericaIn vitro bypass of UV-induced lesions by Escherichia coli DNA polymerase I: specificity of nucleotide incorporation. Proc Natl Acad Sci U S A. 1983 Mar; 80(6):1541-5.Proc Natl Acad Sci U S A1983-03-01T00:00:001983In vitro bypass of UV-induced lesions by Escherichia coli DNA polymerase I: specificity of nucleotide incorporation.Zaupa, CM, Farrell, CJ, Martuza, RL, Rabkin SD.Mol TherInduction of Anti-Tumor Immunity to Murine Neuroblastoma by Flt3-Ligand Generated-Dendritic Cells Loaded with Oncolytic Herpes Simplex Virus-Infected Cells. Mol Ther. 2008; 16:S64.2008-01-01T00:00:002008Induction of Anti-Tumor Immunity to Murine Neuroblastoma by Flt3-Ligand Generated-Dendritic Cells Loaded with Oncolytic Herpes Simplex Virus-Infected Cells22108767Wang J, Hu P, Zeng M, Rabkin SD, Liu RInternational journal of oncologyOncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol. 2012 Mar; 40(3):757-63.Int J Oncol2011-11-21T00:00:002011Oncolytic herpes simplex virus treatment of metastatic breast cancer.Strauss B, Rabkin S, Sagher D.Bishop J, Greaves M, Rowley J, editors. Genes and Cancer.
Interaction of DNA polymerase and adduct conformation in the specificity of incorporation opposite carcinogenic lesions in DNA. Bishop J, Greaves M, Rowley J, editors. Genes and Cancer.
. 1984; 17:157-166.1984-01-01T00:00:001984Interaction of DNA polymerase and adduct conformation in the specificity of incorporation opposite carcinogenic lesions in DNA6182925Moore PD, Rabkin SD, Osborn AL, Strauss BSBiochimieInteractions between DNA polymerase and aminofluorene adducts that affect the recognition and possibly the mutagenicity of the lesions. Biochimie. 1982 Aug-Sep; 64(8-9):757-62.Biochimie1982-08-01T00:00:001982Interactions between DNA polymerase and aminofluorene adducts that affect the recognition and possibly the mutagenicity of the lesions.7584093Wood MJ, Byrnes AP, Pfaff DW, Rabkin SD, Charlton HMGene therapyInflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther. 1994 Sep; 1(5):283-91.Gene Ther1994-09-01T00:00:001994Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors.22929661Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah KMolecular therapy : the journal of the American Society of Gene TherapyMultimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77.Mol Ther2012-08-28T00:00:002012Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.Strauss B, Ayres K, Bose K, Moore P, Rabkin S, Sklar R, Lindgren V.German J. editor. Chromosome Breakage and NeoplasiaMolecular alterations in DNA associated with mutation and chromosome rearrangements. German J. editor. Chromosome Breakage and Neoplasia. 1983; 281-315.1983-01-01T00:00:001983Molecular alterations in DNA associated with mutation and chromosome rearrangements18388912Liu TC, Castelo-Branco P, Rabkin SD, Martuza RLMolecular therapy : the journal of the American Society of Gene TherapyTrichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther. 2008 Jun; 16(6):1041-7.Mol Ther2008-04-01T00:00:002008Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.19351838Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SDCancer researchHuman glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.Cancer Res2009-04-07T00:00:002009Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Rabkin SD, Moulding HDAbs. Soc. NeurosciDefective intracellular protein trafficking of L1 CAM clinical mutants R184Q and D598N. Abs. Soc. Neurosci. 2001.2001-01-01T00:00:002001Defective intracellular protein trafficking of L1 CAM clinical mutants R184Q and D598N10584921Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RLHuman gene therapySystemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999 Nov 20; 10(17):2741-55.Hum Gene Ther1999-11-20T00:00:001999Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.211183Becker Y, Asher Y, Weinberg-Zahlering E, Rabkin S, Friedmann A, Kessler EThe Journal of general virologyDefective herpes simplex virus DNA: circular and circular-linear molecules resembling rolling circles. J Gen Virol. 1978 Aug; 40(2):319-35.J Gen Virol1978-08-01T00:00:001978Defective herpes simplex virus DNA: circular and circular-linear molecules resembling rolling circles.23138870Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RLCancer gene therapyCombination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 2013 Jan; 20(1):17-24.Cancer Gene Ther2012-11-09T00:00:002012Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.Todo T, Rabkin SD, Martuza RL, inventorsThe use of soluble costimulatory factor for tumor immuno-gene therapyThe use of soluble costimulatory factor for tumor immuno-gene therapy. 2006.2006-06-20T00:00:002006The use of soluble costimulatory factor for tumor immuno-gene therapyMartuza RL, Rabkin SD, Mineta T, inventorsReplication-competent herpes simplex virus mediates destruction of neoplastic cellsReplication-competent herpes simplex virus mediates destruction of neoplastic cells. 1996.1996-12-17T00:00:001996Replication-competent herpes simplex virus mediates destruction of neoplastic cells10584932Todo T, Rabkin SD, Chahlavi A, Martuza RLHuman gene therapyCorticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther. 1999 Nov 20; 10(17):2869-78.Hum Gene Ther1999-11-20T00:00:001999Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.10880026Todo T, Rabkin SD, Martuza RLCancer gene therapyEvaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 2000 Jun; 7(6):939-46.Cancer Gene Ther2000-06-01T00:00:002000Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.11196154Todo T, Martuza RL, Dallman MJ, Rabkin SDCancer researchIn situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001 Jan 01; 61(1):153-61.Cancer Res2001-01-01T00:00:002001In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.Martuza RL, Rabkin SD, Mineta T, inventorsReplication-competent herpes simplex virus mediates destruction of neoplastic cellsReplication-competent herpes simplex virus mediates destruction of neoplastic cells. 2004.2004-03-02T00:00:002004Replication-competent herpes simplex virus mediates destruction of neoplastic cells